Directional Asset Management Buys Shares of 19,527 Abbott Laboratories $ABT

Directional Asset Management bought a new position in Abbott Laboratories (NYSE:ABT) in the 4th quarter, Holdings Channel.com reports. The fund bought 19,527 shares of the healthcare product maker’s stock, valued at approximately $2,446,000. Abbott Laboratories comprises approximately 2.1% of Directional Asset Management’s investment portfolio, making the stock its 11th biggest holding.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Capital International Investors boosted its holdings in Abbott Laboratories by 2.5% in the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after purchasing an additional 1,478,076 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Abbott Laboratories by 5.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after buying an additional 821,325 shares in the last quarter. Invesco Ltd. raised its holdings in Abbott Laboratories by 51.0% during the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after buying an additional 4,713,135 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Abbott Laboratories by 3.8% in the third quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock worth $1,804,050,000 after buying an additional 499,351 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Abbott Laboratories by 7.2% during the 3rd quarter. Legal & General Group Plc now owns 12,900,318 shares of the healthcare product maker’s stock worth $1,727,869,000 after acquiring an additional 864,531 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the transaction, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on ABT. Daiwa Securities Group downgraded Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a research note on Wednesday. The Goldman Sachs Group lowered their price target on Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating on the stock in a report on Wednesday, April 8th. Leerink Partners dropped their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday. Sanford C. Bernstein reduced their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.43.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Large-market tailwind: a new IoT medical‑devices market report forecasts strong secular growth for connected and remote-monitoring devices through 2036, supporting Abbott’s device franchises (long-term demand upside). IoT Medical Devices Market Research and Global Forecast Report 2026-2036
• Positive Sentiment: “Most oversold” commentary: coverage noting Abbott as one of the most oversold healthcare names may prompt value-oriented buying and short-covering, supporting near-term rebounds. Abbott is the most oversold healthcare stock as Q1 earnings roll on
• Neutral Sentiment: Elevated investor attention: Zacks and Yahoo note heavy search/interest in ABT, which can increase volatility and trading volume but doesn’t directly change fundamentals. Investors Heavily Search Abbott Laboratories (ABT)
• Neutral Sentiment: Competitive/industry note: unrelated coverage of Intuitive Surgical’s platform refresh highlights competitive dynamics in surgical robotics/devices — worth watching for competitive impact but not an immediate Abbott-specific catalyst. How ISRG Just Secured The U.S. Market
• Negative Sentiment: UBS trims price target to $135 — a reduction in analyst optimism that can cap upside and weigh on investor sentiment despite the company’s solid Q1. UBS Group Cuts Abbott Laboratories (NYSE:ABT) Price Target to $135.00
• Negative Sentiment: Argus issues a pessimistic forecast for ABT — adds to negative analyst noise and could pressure the stock if other firms follow suit. Argus Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price
• Negative Sentiment: Daiwa downgrades ABT to neutral and sets a $92 target — implies limited near-term upside and may influence short‑term seller behavior. Finviz (Daiwa downgrade note)
• Negative Sentiment: Barclays lowers expectations for ABT — another bearish signal from the sell side that contributes to downward pressure on sentiment and potential re-rating risk. Barclays Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $92.45 on Friday. The company has a market cap of $161.02 billion, a price-to-earnings ratio of 25.90, a PEG ratio of 1.53 and a beta of 0.79. The business has a 50 day moving average price of $106.39 and a 200 day moving average price of $117.64. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a twelve month low of $90.72 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The company had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same period in the previous year, the company earned $1.09 earnings per share. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts predict that Abbott Laboratories will post 5.49 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.7%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.